Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria

Reidun Øvstebø1, Marit Hellum2, Hans Christian D Aass3

  • 1Blood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway reidun.ovstebo@ous-hf.no.

Innate Immunity
|September 21, 2013
PubMed

Insights

Eculizumab, a C5 inhibitor, reduced tissue factor (TF) expression and thrombin generation in a model of meningococcal sepsis. This suggests complement C5 plays a key role in sepsis-induced coagulation activation.

Area of Science:

  • Microbiology
  • Immunology
  • Hematology

Background:

  • Neisseria meningitidis causes severe sepsis by activating coagulation and complement systems.
  • Bacterial molecules like lipopolysaccharide (LPS) trigger tissue factor (TF) expression on monocytes and microparticles (MPs).
  • Complement component C5 activation by N. meningitidis also induces TF expression.

Purpose of the Study:

  • To investigate the impact of eculizumab, a C5-blocking antibody, on cell- and MP-associated TF.
  • To explore the interplay between complement and coagulation cascades in meningococcal sepsis.

Main Methods:

  • A whole blood model was used, anticoagulated with lepirudin.
  • Coagulation and complement cascades were activated by N. meningitidis.
  • TF expression (mRNA, protein), TF-dependent thrombin and fibrin generation, and TF-positive MP clot formation were analyzed.

Main Results:

  • Inhibition of C5 significantly reduced cell-associated TF expression at both gene and protein levels.
  • C5 inhibition decreased MP-associated TF-dependent thrombin and fibrin generation.
  • Eculizumab also reduced MP-induced TF-dependent clot formation in whole blood.

Conclusions:

  • Complement component C5 is a critical mediator in N. meningitidis-induced TF expression and subsequent coagulation activation.
  • The complement and coagulation cascades are interconnected in meningococcal sepsis.
  • Targeting C5 may offer a therapeutic strategy for sepsis-induced coagulopathy.